CD274 and neoplasm: Results presented at ESMO 2024 were negative for the primary end-point: in patients with a PD-L1 expression of 25% or higher on tumor cells, DFS was 70 months (durvalumab) and 60 months (placebo), respectively (HR 0.94, 95% CI 0.71–1.25) [13].